Compare Kinder Morgan Inc (KMI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs BIO-TECHNE Corp — how do they compare? Kinder Morgan Inc trades at $31.58 (market cap $69.90B), while BIO-TECHNE Corp trades at $72.12 (market cap $11.24B). The key difference: Kinder Morgan Inc is far larger — about 6.2× BIO-TECHNE Corp's market cap, and Kinder Morgan Inc pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| KMI | TECH | |
|---|---|---|
Market Cap | $69.90B | $11.24B |
Sector | Energy | Health |
52-Week High | $34.31 | $72.29 |
52-Week Low | $25.84 | $43.31 |
Enterprise Value | $101.95B | $11.32B |
Dividend Yield | 3.76% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $30.85, down 1.37% over the past day, with a bearish technical signal from moving averages and oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.37 versus $0.32 expected, and raised full-year guidance. Revenue for 2025 was $16.94 billion, with net income of $3.06 billion and a profit margin of 18.04%. Recent news highlights growth in natural gas infrastructure driven by LNG and power demand, supporting a dividend of $0.30 per share.
KMI presents a mixed outlook; fundamentals are solid with earnings beats and a robust project pipeline, but technical indicators signal near-term caution. Investment opportunities include dividend income and exposure to energy infrastructure growth, while risks involve debt levels and oil price volatility. Analyst consensus is nearly evenly split between buy and hold ratings, reflecting balanced sentiment amid macroeconomic uncertainties.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
